Innovative Radiolabeled Antibody Shows Promise in Cancer Diagnosis and Therapy
Source: The Munich Eye, April 2025
A newly created radiolabeled antibody targeting the cancer-associated antigen IL13R?2 has demonstrated remarkable specificity in binding to cancer cells, while sparing healthy tissues. This advancement, tested across various cancer types, shows promise for enhancing tumor detection and treatment through radioimmunotherapy.
The study, published in the April edition of The Journal of Nuclear Medicine, highlights the potential of interleukin-13 receptor ?-2 (IL13R?2) as a target for noninvasive tumor identification. This receptor is frequently present in solid tumors such as glioblastoma, melanoma, and breast cancer, but is minimally expressed in normal tissues, making it an ideal candidate for targeted therapies.
Researchers noted that there are currently no IL13R?2-targeting antibodies utilized for diagnostic and therapeutic purposes available in clinical settings. The development of a radiolabeled antibody aimed at achieving high tumor uptake and retention is a significant step forward, enabling the delivery of targeted radiation to tumors while minimizing exposure to healthy cells.